Recent FTC Warning Letters Target CBD Medical Claims

September 10, 2019, the U.S. Federal Trade Commission (“FTC”) issued a news release announcing the recent distribution of warning letters to three companies advertising cannabidiol (“CBD”) products as a medical treatment option for a range of various illnesses. Cautioning that such unsubstantiated … Read more about Recent FTC Warning Letters Target CBD Medical Claims

Proposed California CBD Bill Suspended

Contrary to the bill’s projected outcome from earlier in the summer, California lawmakers will not make a decision on Assembly Bill-228 (“AB 228”) this year as the bill has stalled in the state legislature despite broad bipartisan interest and consumer support. Previously expected to be signed into … Read more about Proposed California CBD Bill Suspended

FDA Plans Release of CBD Regulations by Fall 2019

Cannabidiol (“CBD”) products have gained popularity across the country, but clear regulation from the Food and Drug Administration (“FDA”) is still forthcoming. This July, FDA announced an intent to fast- track the process to create these much-needed regulations. Currently, nearly 90% of CBD … Read more about FDA Plans Release of CBD Regulations by Fall 2019

Largest U.S. CBD Company Hit with Warning Letter from FDA

On July 22, 2019, the United States Food and Drug Administration (“FDA”) sent a Warning Letter (the “Letter”) to Curaleaf, Inc. notifying the company that FDA considers several products Curaleaf sells on its website, specifically its  “CBD Lotion,” “CBD Pain-Relief Patch,” five versions of its “CBD … Read more about Largest U.S. CBD Company Hit with Warning Letter from FDA

New Data Projects Decrease in CBD Prices

Cannabidiol (“CBD”) products have garnered unprecedented levels of market interest following the Agriculture Improvement Act of 2018 (“2018 Farm Bill”). Indeed, even though the Food and Drug Administration (“FDA”) still considers ingestible CBD consumer products to be prohibited – the drug Epidiolex … Read more about New Data Projects Decrease in CBD Prices

NFL Announces Research into Cannabis Pain Management

This month, the National Football League (“NFL”) announced that it, along with the National Football League Players Association (“NFLPA”), will be investigating the medicinal potential of cannabis and cannabinoids – such as cannabidiol (“CBD”) - as alternative pain management treatments. In the … Read more about NFL Announces Research into Cannabis Pain Management

Founder and Managing Partner Selected to Testify at FDA Public Hearing

It is with great pride that we announce that our Founder and Managing Partner, Dave Rodman has been selected by the U.S. Food and Drug Administration (“FDA”) to give oral testimony  regarding the safety of products containing cannabis-derived compounds, specifically cannabidiol (“CBD”), at the … Read more about Founder and Managing Partner Selected to Testify at FDA Public Hearing

USPTO Issues Hemp Guidance

Earlier this month, the United States Patent and Trademark Office (“USPTO”) released an official examination guide in response to the Agricultural Improvement Act of 2018 (“2018 Farm Bill”) and associated applications. While the guide offers some clarity for the federal registration of trademarks … Read more about USPTO Issues Hemp Guidance